Effects of Vaginal Lactoferrin Administration Prior to Genetic Amniocentesis on Inflammatory Mediators
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the effect of vaginal lactoferrin administration on
amniotic fluid PGE2 level and MMP-TIMP system in women undergoing genetic amniocentesis. Two
groups of patients will be prospectively enrolled: not treated with lactoferrin and treated
with vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.